Last Updated: August 3, 2026

Litigation Details for Ferring Pharmaceuticals Inc. v. Par Pharmaceutical Inc. (D. Del. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Ferring Pharmaceuticals Inc. v. Par Pharmaceutical Inc. (D. Del. 2015)

Docket 1:15-cv-00173-RGA Date Filed 2015-02-20
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Patents 8,450,338; 8,481,083
Link to Docket External link to docket
Small Molecule Drugs cited in Ferring Pharmaceuticals Inc. v. Par Pharmaceutical Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for Ferring Pharmaceuticals Inc. v. Par Pharmaceutical Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-02-20 133 Final Infringement Contentions for U.S. Patent Nos. 8,450,338 and 8,481,083 filed by Ferring International…20 February 2015 1:15-cv-00173-RGA Patent None District Court, D. Delaware External link to document
2015-02-20 142 Final Infringement Contentions for U.S. Patent Nos. 8,450,338 and 8,481,083 filed by Ferring International…20 February 2015 1:15-cv-00173-RGA Patent None District Court, D. Delaware External link to document
2015-02-20 143 Final Invalidity Contentions for U. S. Patent Nos. 8,450,338 and 8,481,083 filed by Par Pharmaceutical…20 February 2015 1:15-cv-00173-RGA Patent None District Court, D. Delaware External link to document
2015-02-20 192 this ANDA infringes U.S. Patent Nos. 8,450,338 ("the '338 patent") and 8,481,083 ("…the '338 and '083 patents. I. LEGAL STANDARDS A patent is infringed when a person… sells any patented invention, within the United States ... during the term of the patent, ... "…#39;338 PATENTS Plaintiffs assert claims 1, 4-6, 8, 9-12, and 17-18 of the '338 patent and claims…#39;338 patent, then all limitations of the asserted dependent claims of the '338 patent are met. External link to document
2015-02-20 221 Abbreviated New Drug Application infringed U.S. Patent Nos. 8,450,338 and 8,481,083. (Id). Defendant filed its…2015 28 July 2017 1:15-cv-00173-RGA Patent None District Court, D. Delaware External link to document
2015-02-20 36 Initial Infringement Contentions for U.S. Patent Nos. 8,450,338 and 8,481,083 filed by Ferring International…20 February 2015 1:15-cv-00173-RGA Patent None District Court, D. Delaware External link to document
2015-02-20 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,450,338; US 8,481,083. (rwc…20 February 2015 1:15-cv-00173-RGA Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Ferring v. Par (1:15-cv-00173-RGA) Litigation Summary and Patent/Exclusivity Analysis

Last updated: July 4, 2026

Executive summary

  • Case: Ferring Pharmaceuticals Inc. v. Par Pharmaceutical Inc., 1:15-cv-00173-RGA (D. Del., Judge Richard G. Andrews).
  • Core posture: Patent infringement dispute tied to Par’s FDA-approval pathway for a Ferring product (specific asserted patents and product details depend on the pleadings and Orange Book mapping in the case docket).
  • Decision/injunction status: Not enough docket-level decision data is provided here to state what claims survived, whether an injunction issued, or the final outcome.
  • Business relevance: The case is likely a license/settlement or narrowing matter affecting launch timing, market share, and generic entry risk for Par against Ferring.

Content note This litigation summary requires docket-specific facts (asserted patent numbers, asserted counts, claim construction outcomes, trial/bench decision, and any settlement agreement terms). With only the caption and docket number supplied, a complete and accurate analysis cannot be produced.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.